We tested combinations of small-molecule CDK9 and/or BRD4 inhibitors in conjunction with Carboplatin and Paclitaxel and observed a synergistic inhibition of HGSOC ovarian cancer cell growth. The gene discussed is CDK9; the disease is ovarian carcinoma.